Table 3. Therapeutic response of patients and PDTX models.
Case | Stage | Differentiation | Lauren | HER2 expression | Regimen | Clinical response of patients | Concordancea |
---|---|---|---|---|---|---|---|
093 | IV | Poor | Diffuse | Positive | XELOX+Trastuzumab | PR | Yes |
098 | IV | Well | Intestinal | Positive | S-1+Trastuzumab | SD | Yes |
115 | IV | Moderate | Intestinal | Positive | XELOX+Trastuzumab | PR | Yes |
144 | IV | Moderate | Intestinal | Positive | XELOX | SD | No |
156 | IV | Moderate | Intestinal | Negative | DCF | Increased SD | Yes |
Note: PR, partial response; SD, stable disease;
aconcordance: concordance of therapeutic response between patients and PDTX models.